The current leadership of FDA may be softening its stance on peptides—but past patterns suggest the outcome is far from certain. Action Alert!
Listen to the audio version of this article:
THE TOPLINE
- Recent FDA activity—including a planned Pharmacy Compounding Advisory Committee (PCAC) review of peptides like BPC-157 and epitalon—along with changes to the Bulk Drug Substances List, signals a potential shift toward allowing broader access to compounded peptides.
- Despite encouraging signals, PCAC has historically taken a restrictive stance on natural compounds, often recommending limits or bans, raising concerns that the upcoming review may follow the same pattern.
- This process has favored FDA staff perspectives and could ultimately restrict access, reinforcing a pattern where natural therapies are sidelined while similar compounds later emerge as patented pharmaceuticals.
Access to some of the most promising emerging therapies in modern medicine is in peril. Behind the scenes, federal regulators are making decisions right now that could determine whether patients and practitioners can access natural peptide bioregulators—or whether those treatments are effectively pushed out of reach and into pharmaceutical monopolies or unregulated gray markets.
Following several signals from HHS Secretary RFK Jr. that the current administration will protect consumer access to compounded peptides, the FDA has taken two recent actions. A newly announced meeting of the Pharmacy Compounding Advisory Committee (PCAC) on July 23 and 24 has, as part of its agenda, a review of BPC-157 and epitalon. During the forthcoming meeting, the committee will make a recommendation to the FDA as to whether to allow these and other peptides to be compounded.
The FDA has also quietly taken another step: certain peptides are being removed from “Category 2” of the Bulk Drug Substances List which contains substances flagged for safety concerns. Removing peptides from this list is a positive signal that past biases against peptides are being corrected.
Taken together, these developments suggest movement. But whether they will produce meaningful progress remains to be seen.
A Window of Opportunity—Or More of the Same?
We know that RFK Jr. has made public statements in favor of retaining consumer access to peptides. The PCAC, however, has neither been friendly to natural substances in general, nor to peptides in particular.
Historically, the committee has taken a restrictive view of many natural substances, often aligning closely with FDA staff recommendations. PCAC has voted to ban the compounding of curcumin, aloe vera, and a host of other safe, natural compounds. It’s been much the same with peptides so far: PCAC has rejected several peptides for inclusion on the Bulks List, including thymosin alpha-1, despite decades of research supporting its immunological benefits.
ANH attended these PCAC meetings, and time and again we’ve been left with the impression that it is a rigged process. FDA staff are given hours to present the case for why natural substances should be banned from compounding. By contrast, those offering the alternative view are given 15 minutes to present their case for why each peptide should be permitted in compounding.
To be clear, PCAC’s vote is a recommendation. The FDA must go through the formal rulemaking process to ban these substances from compounding. But with RFK Jr.’s public statements in support of peptides, we hope this round of meetings will be different and the process will go beyond the kangaroo court of previous meetings.
A Familiar Pattern
You can reference our previous coverage for how we’ve ended up here. But it’s a familiar story. Natural substances with therapeutic promise are restricted due to theoretical safety risks and/or limited data, even when real-world harm is minimal or undocumented. At the same time, those same compounds often re-emerge later as patented pharmaceutical products.
This dynamic raises a fundamental question: is the FDA really concerned about safety, or about protecting pharmaceutical company profits?
Vigilance Required
There’s no question that recent developments are encouraging. A reopened docket, active FDA review, and signals from political leadership all point to the possibility of change.
Yet the PCAC process has historically narrowed access, not expanded it. If there is to be a genuine shift toward responsible, transparent access to peptides, it won’t happen automatically. It will require continued scrutiny, public engagement, and a willingness to challenge decisions that limit patient choice without clear evidence of harm.
Action Alert!
